Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.,Leukemia

当前位置： X-MOL 学术 › Leukemia › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.
Leukemia ( IF 11.4 ) Pub Date : 2021-11-20 , DOI: 10.1038/s41375-021-01471-3
Susan Bal ₁ , Ehsan Malek ₂ , Ankit Kansagra ₃ , Saad Z Usmani ₄ , Ravi Vij ₅ , Kelly N Godby ₁ , Robert F Cornell ₆ , Yubin Kang ₇ , Elvira Umyarova ₈ , Smith Giri ₁ , Saurabh Chhabra ₉ , Michaela Liedtke ₁₀ , Natalie S Callander ₁₁ , Parameswaran Hari ₉ , Shaji Kumar ₁₂ , Luciano J Costa ₁

Affiliation

Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
University of Texas Southwestern Medical Center, Dallas, TX, USA.
Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
Washington University in St. Louis, St Louis, MO, USA.
Vanderbilt University, Nashville, TN, USA.
Duke University, Durham, NC, USA.
University of Vermont, Burlington, VT, USA.
Medical College of Wisconsin, Milwaukee, WI, USA.
Stanford University, Stanford, CA, USA.
University of Wisconsin, Carbone Cancer Center, Madison, WI, USA.
Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.